Compare · LLY vs PHVS
LLY vs PHVS
Side-by-side comparison of Eli Lilly and Company (LLY) and Pharvaris N.V. (PHVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PHVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 491.7x PHVS ($2.20B).
- Over the past year, LLY is up 48.6% and PHVS is up 75.6% - PHVS leads by 26.9 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 13 for PHVS).
- LLY has more recent analyst coverage (25 ratings vs 13 for PHVS).
- Company
- Eli Lilly and Company
- Pharvaris N.V.
- Price
- $1149.79+1.50%
- $31.68+1.64%
- Market cap
- $1.08T
- $2.20B
- 1M return
- +17.88%
- +6.87%
- 1Y return
- +48.64%
- +75.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 17
- 13
- Recent ratings
- 25
- 13
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks; and PHVS719, a prophylactic extended-release tablet for HAE patients. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Latest LLY
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
Latest PHVS
- Principal Accounting Officer Nijdam Anna sold $82,425 worth of shares (2,670 units at $30.87), decreasing direct ownership by 5% to 46,275 units (SEC Form 4)
- Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
- Director Monges Viviane sold $292,853 worth of shares (9,667 units at $30.29), decreasing direct ownership by 64% to 5,500 units (SEC Form 4) to satisfy tax liability
- Principal Accounting Officer Nijdam Anna exercised 7,330 shares at a strike of $20.00 and sold $225,055 worth of shares (7,330 units at $30.70) (SEC Form 4) to satisfy withholding obligation
- CFO / CLO Nassif David W. sold $303,076 worth of shares (10,000 units at $30.31), decreasing direct ownership by 8% to 120,300 units (SEC Form 4) to satisfy withholding obligation
- Director Bjork Elisabeth exercised 10,000 shares at a strike of $8.05 and sold $293,166 worth of shares (10,000 units at $29.32) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form 4 filed by Chief Executive Officer Modig Berndt
- SEC Form 144 filed by Pharvaris N.V.
- Chief Executive Officer Modig Berndt sold $66,977 worth of shares (2,292 units at $29.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,500 units (SEC Form 4)
- SEC Form 144 filed by Pharvaris N.V.